Evidence map›Paper›PMID 40561143›Full record

ArticlePloS one2025

Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.

Remarh Bsoul, Anja H Simonsen, Kristian S Frederiksen, Kirsten Svenstrup, Sara Bech, Lisette Salvesen, Anne-Mette Hejl, Marcello Rossi, Piero Parchi, Eva L Lund and 1 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Remarh BsoulDanish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-6574-8093
Anja H SimonsenDanish Dementia Research Centre, Copenhagen University Hospital, Copenhagen, Denmark.
Kristian S FrederiksenDanish Dementia Research Centre, Copenhagen University Hospital, Copenhagen, Denmark.
Kirsten SvenstrupDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Sara BechDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Lisette SalvesenDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Anne-Mette HejlDepartment of Neurology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Marcello RossiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Piero ParchiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Eva L LundDanish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-6291-5893
Aušrinė AreškevičiūtėDanish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0003-0202-9942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seeding amplification assays, specifically the Real-Time Quaking-Induced Conversion method (RT-QuIC), have shown great diagnostic potential for α-synucleinopathies. Numerous research groups have demonstrated the method's high sensitivity and specificity using cerebrospinal fluid (CSF) samples and various RT-QuIC workflows. However, establishing a uniform and stably performing RT-QuIC protocol remains challenging. To address this, we established an RT-QuIC protocol with a Universal Control Fluid (UCF), which is simple to adopt, performs stably, and allows uniform preparation of both sample and control reactions. Firstly, we adapted and established a published 48-hour RT-QuIC protocol, including the in-house production of recombinant α-synuclein (rec α-syn), and evaluated its sensitivity and specificity through a blinded screening of an 81 CSF sample cohort consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease, motor neuron disease, multiple system atrophy, unidentified neurodegenerative diseases, and healthy controls. Additionally, we tested all CSF samples in three volumes to determine which volume provides the best diagnostic accuracy. The established RT-QuIC performs nearly equally well with 7 µL and 15 µL added CSF, resulting in 94% and 94.5% diagnostic accuracy, respectively. Secondly, we developed a UCF solution and tested its performance with the established RT-QuIC protocol. Results indicate that UCF, used in defined volume and concentration, standardizes the preparation of both sample and control reactions without compromising the assay's diagnostic accuracy and provides a stabilizing environment for the reactions, ensuring higher reproducibility. The established RT-QuIC protocol for pathologic α-synuclein detection in PD and DLB CSF samples is highly sensitive (92-96%) and specific (93-96%). Therefore, it is important that its adoption in clinical laboratories is uncomplicated and uniform. RT-QuIC with UCF simplifies, standardizes, and stabilizes the assay's performance and, thus, could be recommended as a standard protocol for accurate detection of α-synucleinopathies.

Indexed as

alpha-SynucleinSynucleinopathiesAgedFemaleHumansLewy Body DiseaseMaleMultiple System AtrophyParkinson DiseaseSensitivity and Specificityalpha-Synuclein

Identifiers

PMID40561143
PMCPMC12194165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.